Pfizer places its bet on OTC Nexium

Share this article:
Pfizer places its bet on OTC Nexium
Pfizer places its bet on OTC Nexium

Pfizer is making a multimillion-dollar bet on the over-the-counter (OTC) reflux market. The company is scooping up worldwide marketing rights to the non-prescription version of AstraZeneca's blockbuster proton-pump inhibitor for $250 million up front. AZ would start supplying the OTC med to Pfizer's consumer care unit upon possible approval. The down payment could be a lead-in for additional milestone and royalty payments.

The deal is good for AstraZeneca, which has been slogging through a leadership change, massive layoffs and a failed sepsis drug. A company statement indicated that the deal is also an entry point for further collaboration: AstraZeneca has given Pfizer first refusal rights for the OTC version of the hay fever spray Rhinocort Aqua.

Sales of Nexium's prescription GERD medication, launched in the US in 2001, have been on the decline. Worldwide sales fell to $949 million during the first half of 2012, a 13% drop compared to the same period last year—and last year's sales of $4.4 billion were 12% lower than in 2010. Nexium is slated to lose US patent exclusivity in 2014.

“This agreement will help AstraZeneca realize the substantial, long-term value of this brand and potentially other brands in our portfolio,” Tony Zook, VP of global commercial optimization for AZ, said in a joint company statement.

An OTC version of the drug has not yet been approved, and AstraZeneca will still make the prescription version. An application for the OTC version went before European regulators in June. The companies said the FDA should expect an OTC application in the first half of 2013. Pfizer said in the statement it expects to launch OTC Nexium in the US by 2014.
Share this article:
You must be a registered member of MMM to post a comment.

Next Article in Agency Gallery

Email Newsletters

MM&M Future Leaders

Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 


Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Agency Gallery

Agency Business briefs: June 2014

Agency Business briefs: June 2014

News on Publicis, Palio+Ignite, PulseCX, McCann HumanCare and GolinHarris

It's time to replace the FDA, says Newt Gingrich

It's time to replace the FDA, says Newt ...

Former Speaker of the House and presidential candidate Newt Gingrich has declared that it's time to replace FDA

Agency Business briefs: May 2014

Agency Business briefs: May 2014

Newson ID Media, Frontline Medical Communications and ContextMedia